{"id":"NCT00321672","sponsor":"NeurogesX","briefTitle":"Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy","officialTitle":"A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2006-05-04","resultsPosted":"2011-06-14","lastUpdate":"2011-06-14"},"enrollment":494,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain","HIV Infections","Peripheral Nervous System Diseases"],"interventions":[{"type":"DRUG","name":"NGX-4010, 8% capsaicin patch","otherNames":["the brandname of NGX-4010, 8% capsaicin patch is Qutenza."]},{"type":"DRUG","name":"0.04% capsaicin patch","otherNames":["NGX-4010"]},{"type":"DRUG","name":"NGX-4010, 8% capsaicin patch","otherNames":["The brandname of NGX-4010, 8% capsaicin patch is Qutenza."]},{"type":"DRUG","name":"0.04% capsaicin patch","otherNames":["NGX-4010"]}],"arms":[{"label":"NGX-4010, 60 minutes","type":"EXPERIMENTAL"},{"label":"NGX-4010, 30 minutes","type":"EXPERIMENTAL"},{"label":"0.04% conc. capsaicin patch, 60 min.","type":"OTHER"},{"label":"0.04% conc. capsaicin patch, 30 min.","type":"OTHER"}],"summary":"The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy.","primaryOutcome":{"measure":"The Primary Measure of Efficacy Was the Percent Change in the \"Average Pain for the Past 24 Hours\" Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to 12.","timeFrame":"Weeks 2-12","effectByArm":[{"arm":"NGX-4010, 60 Minutes","deltaMin":-32.8,"sd":2.41},{"arm":"Control Group, 60 Minutes","deltaMin":-30,"sd":3.27},{"arm":"NGX-4010, 30 Minutes","deltaMin":-26.2,"sd":2.39},{"arm":"Control Group , 30 Minutes","deltaMin":-19.1,"sd":3.61},{"arm":"NGX-4010 Total","deltaMin":-29.5,"sd":1.7},{"arm":"Control, Total","deltaMin":-24.5,"sd":2.43}],"pValues":[{"comp":"OG004 vs OG005","p":"0.0967"},{"comp":"OG000 vs OG001","p":"0.4884"},{"comp":"OG002 vs OG003","p":"0.1031"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23351618","22067661"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":165},"commonTop":["Application site pain","Application site erythema","Peripheral sensory neuropathy","Pain in extremity","Erythema"]}}